Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

Posted: May 15, 2022 at 2:13 am

SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.

See the original post:
Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

Related Posts